About Event
Welcome to the 3rd Induced Proximity-Based Drug Discovery Summit
As the only industry-dedicated meeting focused on next-generation of heterobifunctional drugs, the 3rd Induced Proximity-Based Drug Discovery Summit will bring together 60+ key opinion leaders to advance fragment-based drug discovery, predict ternary complex formation, and accelerate gain of empirical proof.
Industry leaders such as Bristol Myers Squibb, Nurix and Progenra will deliver technical, data-led seminars and workshops while new players like Stablix, Halda Therapeutics and Gandeeva Therapeutics will reveal new data.
Use this exclusive opportunity to network with a highly senior, technical crowd composed of CXOs, VPs, Senior Directors and Heads of Induced Proximity Platforms, Drug Discovery, and Chemical Biology as well as key academic leaders.
Why Attend?

Explore the burgeoning potential of the induced proximity field with a full day dedicated to emerging novel modalities

Accelerate the speed of novel binder discovery via high throughput screening platforms to develop the most promising fragments into heterobifunctionals

Leverage AI and computational chemistry to predict protein interactions early in the design process, enabling progression from “serendipity” to rational design

Promote stable ternary complex formation between your protein of interest and cellular machinery to promote co-operative interactions